Management of Febrile Neutropenia in the UK: A Survey
Author Information
Author(s): Innes H, Billingham L, Gaunt C, Steven N, Marshall E
Primary Institution: Clatterbridge Centre for Oncology, Cancer Research UK Institute for Cancer Studies
Hypothesis
Are recent advances in the management of febrile neutropenia being implemented in routine clinical practice in the UK?
Conclusion
The study found significant variation in the management of febrile neutropenia among UK clinicians, with a slow adoption of newer treatment strategies.
Supporting Evidence
- Only 38% of clinicians stratify patients according to risk.
- Only 22% of clinicians use oral antibiotics as first-line treatment.
- 84% of respondents are willing to participate in a trial of oral antibiotics combined with early discharge.
Takeaway
Doctors in the UK are not using the latest treatments for patients with febrile neutropenia as much as they should, even though many are willing to try new methods.
Methodology
Questionnaires were sent to cancer clinicians across the UK to assess their management practices for febrile neutropenia.
Potential Biases
Responses may reflect the practices of clinicians who are more engaged with clinical trials, potentially skewing the results.
Limitations
The study may overestimate the use of oral antibiotics as it surveyed clinical trialists who might be more aware of recent evidence.
Participant Demographics
Clinicians from 50 cancer departments across the UK, including 94 clinical/medical oncologists and 32 haematologists.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website